Strategic Partnerships Dyne Therapeutics operates at the intersection of neuromuscular genetic diseases and targeted delivery, presenting opportunities for collaborations with gene therapy companies, contract development and manufacturing organizations (CDMOs), and academic partnerships to advance muscle and CNS targeted therapeutics.

Expansion Opportunities With programs in Duchenne muscular dystrophy, DM1, and preclinical work in FSHD and Pompe disease, there are multiple entry points for co-development, licensing, or strategic funding to accelerate preclinical-to-clinical transitions and broaden the portfolio.

TfR1 PLATFORM Dyne’s TB1-targeted FORCE conjugates and DYNE-101/ DYNE-251 assets indicate a differentiated delivery platform appealing to partners seeking improved tissue targeting and payload delivery for neuromuscular indications.

Commercial Readiness Significant funding and sizable clinical pipeline alongside revenue generation potential position Dyne for license-out or co-commercial arrangements with larger biopharma, particularly for rare neuromuscular diseases with unmet needs.

Key Engagements Active presence at major conferences and ongoing preclinical data dissemination create opportunities for early-stage investor and partner outreach, enabling strategic introductions to decision-makers in neuromuscular, biotech investment, and collaboration ecosystems.